Interferon-beta treatment of human disease.
After nearly 20 years in the clinic, the benefits of interferon-beta treatment in specific disease states are being recognized increasingly. Two major clinical studies completed within the past two years have firmly established the use of this drug in the treatment of multiple sclerosis. Its therapeutic activity in several indications, including acute and chronic viral hepatitis, has also been demonstrated; however, the general use of interferon-beta in these settings awaits the results of ongoing studies and the development of practical dosing regimens.
Biogen Corporation, Cambridge, USA.
J J
JJ
Alam
D000818:Animals; D001709:Biotechnology; D002986:Clinical Trials as Topic; D006525:Hepatitis, Viral, Human / Q000628:therapy; D006801:Humans; D016899:Interferon-beta / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000628:therapy; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D016899:Interferon-beta